CTMX—(-37%/AH)—My reading of the PR is that they had only 2 partial responses among 51 enrolled patients in all cancer types. The PR obfuscates, but it didn’t fool investors, evidently.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.